194 related articles for article (PubMed ID: 30394560)
1. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
[No Abstract] [Full Text] [Related]
2. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Foyil KV; Kennedy DA; Grove LE; Bartlett NL; Cashen AF
Leuk Lymphoma; 2012 Mar; 53(3):506-7. PubMed ID: 21867368
[No Abstract] [Full Text] [Related]
3. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M; Ehninger G
Ann Hematol; 2013 Jan; 92(1):125-7. PubMed ID: 22820970
[No Abstract] [Full Text] [Related]
4. [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
Sun XF; Zhen ZJ; Xiang XJ; Ling JY; Peng RJ; Xia Y; Zheng L; Luo WB; Lin H; Guan ZZ
Ai Zheng; 2009 May; 28(5):506-10. PubMed ID: 19624879
[TBL] [Abstract][Full Text] [Related]
5. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
8. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ
Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022
[No Abstract] [Full Text] [Related]
9. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
[No Abstract] [Full Text] [Related]
11. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Short NJ; Kantarjian HM; Ko H; Khoury JD; Ravandi F; Thomas DA; Garcia-Manero G; Khouri M; Cortes JE; Wierda WG; Verstovsek S; Estrov Z; Ferrajoli A; Thompson PA; Pierce S; O'Brien SM; Jabbour E
Am J Hematol; 2017 Jun; 92(6):E114-E117. PubMed ID: 28295472
[No Abstract] [Full Text] [Related]
13. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Isogai R; Fukao M; Kawada A
J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
[TBL] [Abstract][Full Text] [Related]
15. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
16. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
17. "Double hit" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.
Luo DX; Li W; Ye MT; Yang Y; Tang G; You MJ
Am J Hematol; 2020 Dec; 95(12):1625-1627. PubMed ID: 32833271
[No Abstract] [Full Text] [Related]
18. Bilateral sciatic nerve neurolymphomatosis: PET/CT findings.
Gorospe L; Gallego-Rivera JI; Rioja-Martín ME; Chinea-Rodríguez A
Ann Hematol; 2017 Jun; 96(6):1059-1060. PubMed ID: 28374164
[No Abstract] [Full Text] [Related]
19. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Calleja A; Bouclet F
Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
[No Abstract] [Full Text] [Related]
20. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin.
Abid MB; Wang S; Loi HY; Poon LM
Ann Hematol; 2016 Oct; 95(10):1725-6. PubMed ID: 27460479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
